Synbiotic Supplementation Improves Metabolic Factors and Obesity Values in Women with Polycystic Ovary Syndrome Independent of Affecting Apelin Levels: A Randomized Double-Blind Placebo-Controlled Clinical Trial

Sima Darvishi, M.Sc.1, Maryam Rafraf, Ph.D.2, Mohammad Asghari-Jafarabadi, Ph.D.2,4, Laya Farzadi, M.D.5

1. Student’s Research Committee, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
2. Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
3. Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4. Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran
5. Department of Obstetrics and Gynecology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Background: This research investigated the symbiotic supplement influences on serum glycemic indices and lipids as well as apelin rates and obesity values in polycystic ovary syndrome (PCOS) patients.

Materials and Methods: A total of 68 obese or overweight patients (20-44 years old) with PCOS were enrolled to conduct a randomized double-blinded placebo-controlled clinical trial. A total of 34 people in the synbiotic group received a synbiotic supplement and 34 people in the placebo group received placebo, daily for 8 weeks. Fasting blood specimens, anthropometric measurements and dietary intake data were gathered three times during the study. The information was analyzed by independent t test, paired t test, analysis of covariance and chi-square test.

Results: Synbiotic supplementation significantly decreased serum fasting glucose (P=0.02), insulin (P=0.001), homeostatic model assessment for insulin resistance (IR, P=0.001), weight (P=0.02), body mass index (BMI, P=0.02), waist circumference (WC, P=0.01), hip circumference (HC, P=0.02), and waist-to-height ratio (WHtR, P=0.02) but significantly increased high-density lipoprotein (HDL) cholesterol (P=0.02) compared to the placebo. At the end of the trial, no significant differences were seen in serum total cholesterol, triglyceride (TG), low-density lipoprotein (LDL) cholesterol, or apelin levels as well as waist-to-hip ratio (WHR) between the two groups.

Conclusion: Synbiotic supplementation improved glycemic indices, lipid profile and obesity values in women with PCOS. These beneficial effects were not related with alterations in serum apelin levels (Registration number: IRCT20100408003664N19).

Keywords: Apelin, Metabolic Factors, Obesity, Polycystic Ovary Syndrome, Synbiotic

Introduction

Polycystic ovary syndrome (PCOS) is a momentous endocrine disarray in reproductive age women that leads to infertility and an enhancement in the occurrence of abortion, gestational diabetes and pre-eclampsia (1, 2). The prevalence of PCOS is estimated to be 4 to 21% worldwide (3). These patients indicate an irregular menstruation period, an ovulatory cycle, and androgen excess (4).

PCOS is contemplated as a multifactorial disease that is often accompanied by metabolic disorders including obesity, insulin resistance (IR), dyslipidemia and increased levels of androgens. PCOS is a risk factor for type 2 diabetes, cardiovascular difficulties and endometrial cancers (2, 5).

More than 50% of patients with PCOS are obese (6). Adipose tissue generates several proteins that are called adipokines that have a hormonal function (7). Studies have shown that adipokines derived from fatty tissue, can contribute to the pathogenesis of PCOS (8). Apelin (APLN-13or -17) is an adipokine located on the Xq25-q26 chromosome and it contains 77 amino acids. Adipose tissue is not the only determinant of serum apelin levels. Other organs such as the ovary, breast, gastrointestinal system, and central nervous system can also contribute to apelin secretion (9). It has been proposed that apelin has a function in regulating glucose metabolism, lipolysis and food intake (10). Some studies stated
that apelin has a significant function in controlling IR in diabetes mellitus type 2 mice and humans (11, 12).

The implication of apelin in the pathogenesis of PCOS seems to be more intricate, involving a disrupted synthesis of androgens (13, 14). Lifestyle modification such as weight loss and using oral contraceptive pills and metformin are the most common treatments for PCOS (5, 15). Recently, modulation of intestinal microbiota equilibrium using probiotics and prebiotics has been suggested as an effective approach for some diseases such as PCOS. The intestinal microbiota imbalance can lead to increased ovarian androgen production and prevents the spread of the natural follicles of the ovary through chronic inflammatory response and IR (15). Living microorganisms called probiotics concede a well profit up on the hostess until used with adequate quantities (16). On the other hand, prebiotic is as "a non-digestible food component" that lucratively affects the host via selectively promoting the development and/or activity of one or a confined number of bacteria in the colon (17).

A composition of probiotic and prebiotic that augment the viability of probiotics in the intestinal tract by stimulating growth or betterment metabolic activity, is called symbiotic (18). Samimi et al. (19) presented that symbiotic supplementation for 12 weeks, declined IR and serum levels of insulin, very-low-density lipoprotein (VLDL) cholesterol and triglyceride (TG) in PCOS patients. Karimi et al. (20) reported that symbiotic supplementation at a dose of 1000 mg for 12 weeks, reduced serum apelin-36 levels in PCOS patients, although changes in IR, blood glucose and insulin levels were not significant. In another study, symbiotic supplementation for 12 weeks led to a notable reduction in serum insulin levels and IR in patients with PCOS (21). There is no further study about the effect of symbiotics in patients with PCOS.

Since variations in gut microbiota combination have been reported in subjects with PCOS (22), symbiotics can be considered as remedial agents (15). However, controversies have been seen in the outcomes of studies (19, 21). Moreover, the effects of symbiotics supplementation on obesity values have not been assayed in these patients. Accordingly, we designed a study to assess the effects of symbiotics on glycemic indices, serum lipids, and apelin levels and anthropometric values in PCOS patients.

Materials and Methods

In this randomized double-blinded placebo-controlled clinical trial study, out of 68 people suffering from PCOS within the age range 20-44 years and with body mass index (BMI) ranged 25-40 kg/m² cooperated in this randomized double-blinded placebo-controlled clinical trial in Alzahra Hospital in General Gynaecology Clinic Department, in Tabriz, between June and December 2018.

The sample size was calculated based on information obtained from the research conducted by Ahmadi et al. (23) on IR. The sample size was calculated as 30 in each group, for the confidence intervals of 95% and a power of 80%. The projected dropout rate was set at 34 with the increase in sample size per group. 2003 Rotterdam criteria determined cognitive performance in PCOS due to three dimensions such as: idiopathic amenorrhea or oligomenorrhea, presenting the hyperandrogenism (convenient clinical and/or biochemical assessments) and PCOS via sonography (8).

Criteria for exclusion included: thyroid gland disorders, diabetes, high levels of serum prolactin (hyperprolactinemia), gestation and lactation, liver or kidney disease, Cushing's syndrome diseases, cardiovascular diseases, high blood pressure, drug consumption including hydrochlorothiazide, insulin therapy, using beta blockers, low-density lipoprotein (LDL) cholesterol medicine, addiction, fertility treatments available, using cortisone-like medicine, following a special diet as well as being athlete or sport in orderly array (longer than the standard 2-week), antibiotic use during the last month and at the time of the study, use of any dietary supplements in the last 2 months or throughout the study, receiving probiotics, prebiotics and symbiotics in the last three months and simultaneous of the study, regular consumption of probiotic products and sensitivity to symbiotic or probiotic capsules.

The research protocol was approved by the Research Ethics Committee of Tabriz University of Medical Sciences (code: IR.TBZMED.REC.1396.1080) and registered at the IRCT website (Registration number: IRCT20100408003664N19). Written informed consent was gained from all participating women before the study.

Based on the age and BMI, the participants were randomly divided into two groups by a size 2 block randomization technique. In this technique, patients had to retain a normal diet and physical activity throughout the trial.

Public information was obtained for each participant. Body weight and height were measured using a scale (Seca, Germany), and a mounted tape, respectively. BMI was estimated by dividing the weight in kilogram by height in (m²). Soft measuring tape in standing up position was used to obtain hip circumference (HC) as well as waist circumference (WC) (24). WC was measured in the narrowest section across the costaarch and the crest of the ilium and HC as the distance around the largest part of hips. Waist-to-hip ratio (WHR) and waist-to-height ratio (WHr) were respectively calculated as follows: WC in centimeter divided by HC in centimeter and WC in centimeter divided by height in centimeter.

Validated International Assessment of Physical Activity Questionnaire (IPAQ) was used to estimate the level of physical activity (25).

Also, 24-hour method was used to acquire data on daily intake of energy and macronutrients (2 week days and 1 weekend day). Questionnaires were completed before starting the study, at the end of the fourth week and the end of the study. The average energy and macronutrients intakes of all patients were analyzed using Nutritionist 4 software (FDBInc., California).
For eight weeks, patients in the treatment group (n=34) received one capsule of synbiotic and placebo group (n=34) received placebo capsule that was essential in daily use after lunch.

Each synbiotic capsule (500 mg, Zist-Takhmir Co., Iran), included seven strains of helpful bacteria (Lactobacillus casei 3×10^8 colony-forming units (CFU)/g, genus Lactobacillus Lactobacillus rhamnosus 7×10^6 CFU/g, Lactobacillus bulgaricus 5×10^8 CFU/g, genus Lactobacillus acidophilus 3.1010 CFU/g, Bifidobacterium longum subsp1×10^6 CFU/g, (strainACS-071-V-Sch8b) 2×10^8 CFU/g and Streptococcus thermophilus subsp3×10^8 CFU/g and inulin-type prebiotics (Fructooligosaccharides (FOS)). The placebo capsule contained starch with identical color and form.

The compliance of the participants with the study protocol was evaluated via phone talks once per week and by assessment of returned capsules every 2 weeks.

**Blood sampling and biochemical assays**

Blood samples (5 mL) were collected after 12-hour overnight fasting, in the morning. The serum was separated via centrifugation and stored at -70°C up to subsequent research. The standardized enzymatic method using a commercially available Kit (Pars Azmoon, Iran) was employed to evaluate blood glucose. ELISA method using Monobind kit (Monobind Inc., CA, USA) was used to measure the serum insulin level and IR was defined via Homeostasis Model Assessment (HOMA) equations using the following relation: HOMA-IR was estimated by multiplying the fasting insulin (μIU/mL) and fasting glucose (mg/dL) divided by 405 (26).

Standardized enzymatic approach using a commercially available Kit (Pars Azmoon, Iran) was employed to evaluate the total blood cholesterol (TC), TG, and high-density lipoprotein (HDL) cholesterol. Serum concentration of LDL cholesterol was quantified via Friedewald formula (FF): LDL cholesterol=TC-(HDL cholesterol+TG/5) (27). Enzyme-linked Immunosorbent Assay (shortened as ELISA) using Mediagnost kit (Cat No. E2037Hu; Shanghai Crystal Day-Biotech Co., Ltd) was used to measure the serum apelin ratio.

The inter-and intra-assay coefficients of variation toward apelin were considered lower than 8 and 10%, respectively.

Finally, all the body measurements, and biochemical assessments were reassessed at the end of the study.

**Statistical analysis**

Statistics SAGE IBM® SPSS® Statistics 23 software was used to analyze the data (supplied by SPSS Inc., USA) and findings are presented as mean ± SD. The distribution of variables was normal as assessed by Kurtosis-Skewness statistics. Independent t test was used for comparing primary evaluations of all variables in the two groups at the baseline and (χ^2) criterion was also used for categorical and numeric variables. Changes in body measurements and blood parameters of patients were measured between pre-test and post-test by paired-samples t test. Analysis of covariance (ANCOVA) was applied to recognize any discrepancies between the two groups after the supplementation, adjusting for baseline measurements and confounders. Repeated measures ANCOVA were exerted to assess the within-group changes in dietary intake. The following equation determined the variable alterations after intervention by percentage: [(subtraction of after and before values) divided by before values] multiplied by 100. Statistical significance was considered at P<0.05.

**Results**

All participants [the synbiotic group (n=34) as well as the placebo group (n=34)] ended the study (Fig.1). The adoption of the study was performed well and 95% of the prescribed supplements were consumed during the study. No complication or symptoms were reported following supplementation.

Public characteristics of the patients are shown in Table 1. There were no significant discrepancies between the two groups in the means of age, weight, BMI and physical activity levels at baseline. No groups had significant changes (P<0.05) in the rate of women’s physical activity during the study.

**Table 1: General features of women with PCOS participated in this trial**

| Variable          | Measurement period | Placebo group n=34 | Synbiotic group n=34 | MD (95% CI), P value |
|-------------------|--------------------|--------------------|----------------------|----------------------|
| Age (Y)           | Baseline           | 28.6 ± 4.82        | 30.4 ± 5.82          | 2.47 (-3.8 to 8.82), 0.438 |
| Weight (kg)       | Baseline           | 73.67 ± 10.89      | 76.15 ± 14.97        | 0.95 (-1.34 to 3.26), 0.409 |
| BMI (kg/m^2)      | Baseline           | 28.47 ± 3.55       | 29.43 ± 5.69         | 0.564^               |
| Physical activity | Baseline           | Low 19 (55.9)      | 16 (47.1)            |                      |
|                   |                    | Moderate 8 (23.5)  | 14 (41.2)            |                      |
|                   |                    | High 7 (20.6)      | 4 (11.8)             |                      |
|                   | After intervention | Low 1 8 (52.9)    | 14 (41.2)            | 0.328^               |
|                   |                    | Moderate 9 (26.6)  | 15 (44.1)            |                      |
|                   |                    | High 7 (20.5)      | 5 (14.7)             |                      |

Data are presented as mean ± SD or n (%); PCOS; Polycystic ovary syndrome, CI; Confidence interval, MD; Means difference, BMI; Body mass index, and *; P value is reported based on the chi-square test. MD (95% CI); P value is reported based on the analysis of independent sample t test.
Table 2: Dietary intakes of women with PCOS participated in this trial at baseline and after 8 weeks of intervention

| Variable       | Measurement period | Placebo group n=34 | Synbiotic group n=34 | P value  |
|----------------|--------------------|--------------------|----------------------|---------|
| Energy (kcal/day) | Before             | 1528.19 ± 300.87   | 1759.08 ± 511.30     | 0.027*  |
|                | Fourth week        | 1682.55 ± 360.35   | 1847.06 ± 387.35     | 0.517** |
|                | After              | 1636.36 ± 286.46   | 1796.08 ± 423.39     | 0.566** |
|                | P value†           | 0.021              | 0.391                |         |
| Carbohydrate (g/day) | Before           | 217.46 ± 50.16     | 257.47 ± 94.69       | 0.033*  |
|                | Fourth week        | 230.94 ± 60.64     | 259.65 ± 59.78       | 0.347   |
|                | After              | 235.58 ± 54.12     | 256 ± 67.51          | 0.804   |
|                | P value†           | 0.143              | 0.954                |         |
| Protein (g/day)  | Before             | 51.40 ± 12.74      | 58.54 ± 20.83        | 0.093   |
|                | Fourth week        | 56.68 ± 15.68      | 61.78 ± 14.89        | 0.610   |
|                | After              | 53.06 ± 13.70      | 60.17 ± 15.46        | 0.207   |
|                | P value†           | 0.190              | 0.519                |         |
| Total fat (g/day) | Before             | 52.80 ± 14.69      | 57.31 ± 15.48        | 0.223   |
|                | Fourth week        | 61.68 ± 16.83      | 64.18 ± 22.86        | 0.905   |
|                | After              | 56.04 ± 12.84      | 62.03 ± 20.70        | 0.316   |
|                | P value†           | 0.015              | 0.097                |         |

Data are presented as mean ± SD. PCOS: Polycystic ovary syndrome. †: Significant difference between the two groups at baseline (P<0.05, independent sample t test). ‡: P value is reported based on the analysis of the repeated measures, and ‡‡: P value is reported based on analysis of covariance (adjusted for baseline values).
Daily dietary intakes of patients throughout the study are shown in Table 2. There were significant differences (P<0.05) between the two groups in average of daily energy and carbohydrate intakes at baseline. Diversities in other macronutrients intake were not notable between the two groups at baseline. There was a significant increase in energy and whole lipid intake in the placebo group (by 1.35, 13.92 and 15.68% at blood ratios of glucose, insulin and HOMA-IR and 2.88% increase in HDL cholesterol, in comparison to the baseline values. Also, serum ratios for glucose increased within the placebo group (by 6.08 %, respectively) in the synbiotic group at the end of the trial in comparison to the baseline values. There were no significant alterations in blood TC, TG, LDL cholesterol and apelin levels.

Supplementation with symbiotic reduced by respectively 1.35, 13.92 and 15.68% at blood ratios of glucose, insulin and HOMA-IR and 2.88% increase in HDL cholesterol, in comparison to the placebo group.

Table 3 shows a substantial reduction in insulin and HOMA-IR (by 13.92%, P<0.02 and 15.68%, P<0.03, respectively) in the symbiotic group at the end of the trial in comparison to the baseline values. Also, serum ratios for glucose increased within the placebo group (by 6.08 %, P<0.001). Serum apelin concentrations stayed unchanged in the two groups at the end of the study. The baseline and post-intervention values for apelin levels which had a wide set toward energy intake, BMI as well as initial amounts. There were no significant alterations in other parameters.

Results of analysis of covariance indicated statistically considerable variations between the two studied groups in serum levels of glucose (P=0.02), insulin (P=0.001), HOMA-IR (P=0.001) and HDL cholesterol (P=0.02) finally, set toward energy intake, BMI as well as initial amounts. There were no significant alterations in blood TC, TG, LDL cholesterol and apelin levels.

### Table 3: Biochemical parameters of women with PCOS participated in this trial, at baseline and after 8 weeks intervention

| Variable           | Measurement period | Placebo group n=34 | Symbiotic group n=34 | MD (95% CI), P value |
|--------------------|--------------------|---------------------|----------------------|---------------------|
| Glucose (mg/dL)    | Baseline           | 89.02 ± 9.05        | 91.32 ± 8.07         | 2.29 (-1.86 to 6.45), 0.274 |
|                    | After intervention | 94.44 ± 9.49        | 90.08 ± 7.90         | -4.52 (-8.50 to -0.54), 0.026† |
|                    | MD (95% CI), P value | 5.41 (2.38 to 8.43), 0.001** | -1.2 (-4.58 to 2.11), 0.459 |
| Insulin (μIU/mL)   | Baseline           | 9.46 ± 4.64         | 13.36 ± 4.89         | 3.89 (1.58 to 6.20), 0.001† |
|                    | After intervention | 13.17 ± 5.29        | 11.50 ± 4.75         | -3.90 (-6.18 to -1.62), 0.001† |
|                    | MD (95% CI), P value | 3.70 (2.06 to 5.34), 0.000** | -1.85 (-3.41 to -0.29), 0.021** |
| HOMA-IR            | Baseline           | 2.10 ± 1.12         | 3.06 ± 1.35          | 0.95 (0.35 to 1.55), 0.002† |
|                    | After intervention | 3.08 ± 1.31         | 2.58 ± 1.15          | -0.93 (-1.50 to -0.36), 0.001† |
|                    | MD (95% CI), P value | 0.97 (0.56 to 1.39), 0.000** | -0.47 (-0.90 to -0.04), 0.032** |
| TC (mg/dL)         | Baseline           | 197.91 ± 39.80      | 209.41 ± 33.16       | 11.50 (-6.25 to 29.25), 0.200 |
|                    | After intervention | 210.11 ± 39.17      | 208.55 ± 38.92       | -6.93 (-22.58 to 8.71), 0.379 |
|                    | MD (95% CI), P value | 12.20 (3.09 to 21.31), 0.010** | -0.85 (-13.92 to 12.21), 0.895 |
| TG (mg/dL)         | Baseline           | 140.76 ± 71.22      | 139.29 ± 69.92       | -1.47 (-35.64 to 32.70), 0.932 |
|                    | After intervention | 149.14 ± 83.83      | 137.97 ± 68.61       | -11.88 (-31.79 to 8.03), 0.238 |
|                    | MD (95% CI), P value | 8.38 (-5.23 to 22), 0.219 | -1.32 (-15.20 to 12.55), 0.847 |
| LDL-cholesterol (mg/dL) | Baseline           | 121.61 ± 31.64      | 135.75 ± 28.40       | 14.14 (-0.41 to 28.71), 0.057 |
|                    | After intervention | 136.05 ± 32.60      | 133.84 ± 36.07       | -8.34 (-24.11 to 7.42), 0.294 |
|                    | MD (95% CI), P value | 14.44 (5.77 to 23.10), 0.002** | -1.91 (-14.74 to 10.92), 0.764 |
| HDL-cholesterol (mg/dL) | Baseline           | 48.14 ± 10.22       | 45.79 ± 12.05        | -2.35 (-7.76 to 3.06), 0.389 |
|                    | After intervention | 44.23 ± 10.73       | 47.11 ± 12.73        | 5.39 (0.74 to 10.05), 0.024† |
|                    | MD (95% CI), P value | -3.91 (-7.91 to 0.09), 0.055 | 1.32 (-1.25 to 3.90), 0.304 |
| Apelin (nmol/mL)   | Baseline           | 28.12 ± 23.56       | 20.06 ± 13.78        | -8.06 (-19.53 to 3.41), 0.164 |
|                    | After intervention | 32.93 ± 25.88       | 21.86 ± 14.87        | -0.81 (-10.88 to 9.25), 0.871 |
|                    | MD (95% CI), P value | 4.80 (-0.96 to 10.57), 0.098 | 1.80 (-5.47 to 9.07), 0.613 |

Data are presented as mean ± SD. PCOS; Polycystic ovary syndrome, CI; Confidence interval, MD; Means difference, HOMA-IR; Homeostatic model assessment for insulin resistance, TC; Total cholesterol, TG; Triglyceride, LDL; Low-density lipoprotein, HDL; High-density lipoprotein, BMI; Body mass index, †; P value is reported based on the analysis of independent sample t test, **; P value is reported based on the analysis of paired sample t test, and †; P value is reported based on the analysis of covariance, adjusted for energy intake, BMI and baseline values.
at baseline and after 8-weeks supplementation are shown in Table 4. There were no considerable differences between the two groups in weight, BMI, HC, WHR and WHtR at baseline.

Results of analysis of covariance illustrated a statistically significant discrepancy between the two studied groups in weight (P=0.02), BMI (P=0.02), HC and WHR (P=0.01, P=0.02, respectively) and WHtR (P=0.02) at the end of the study, adjusted for energy intake and baseline values. Changes in WHR was not significant between the two groups at the end of the study (P>0.05).

Significant decreases (by 2.52% and 1.75%, respectively) were observed in WC and WHtR of subjects in the synbiotic group after the intervention compared to the baseline values (P=0.009 and P=0.02, respectively). Changes in other anthropometric variables were not significant within the synbiotic group. Weight and BMI increased within the placebo group (respectively by 0.74%, P=0.003 and 0.87%, P=0.003).

Discussion

The application of probiotics and prebiotics can ameliorate the contrast between intestinal microbiota and host metabolism in obesity and associated metabolic diseases (28). Few studies assessed potential influences of synbiotics in subjects with PCOS. To the best of our knowledge, impacts of synbiotics on lipids profile and obesity values have not been investigated in subjects with PCOS by a supplement similar to that used in our study with respect to form, dose, strains, and duration of use.

In a previous study about synbiotic supplementation in PCOS patients that assessed glycemic indices and apelin levels, 1000 mg dosage of the capsule (20) was used, which was different from our study (i.e. 500 mg).

According to findings of present trial, synbiotic supplementation reduced fasting blood glucose, HOMA-IR and insulin in patients during eight weeks of supplementation. Our results are in accordance with the findings reported by Samimi et al. (19) which showed that the use of one synbiotic capsules (genera Lactobacillus, L. casei, and B. bifidum, 2×10^9CFU/g together with 800 mg inulin) per day for 12 weeks, reduced serum insulin and HOMA-IR in PCOS women. Esmaeilinezhad et al. (29) reported that consumption of synthetic pomegranate juice and synthetic beverage (2 L/week) for 8 weeks, lowered HOMA-IR in women with PCOS.

It was suggested that synbiotics may play a momentous role in the metabolism of carbohydrates by producing short-chain fatty acids (SCFAs). SCFAs bind to G protein-coupled receptors and increase the secretion of glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), from enteroendocrine L-cells which can trigger insulin production by pancreatic β cells, inhibit glucagon secretion, decrease hepatic gluconeogenesis, and raise insulin sensitivity (17). Synbiotics also improve bowel function, elevate the production of mucin and diminish the amount of gram-negative (inappropriate) bacteria in the colon. These changes decrease the transmission of

### Table 4: Anthropometric characteristics of subjects with PCOS participated in this trial, at baseline and after 8 weeks of intervention

| Variable   | Measurement period | Placebo group n=34 | Synbiotic group n=34 | MD (95% CI), P value |
|------------|--------------------|---------------------|----------------------|---------------------|
| Weight (kg) | Baseline           | 73.67 ± 10.89       | 76.15 ± 14.97        | 2.47 (-3.8 to 8.82), 0.438 |
|            | After intervention | 74.22 ± 11.14       | 75.08 ± 15.35        | -1.58 (-2.91 to -0.24), 0.021† |
| BMI (kg/m²) | Baseline           | 28.47 ± 3.55        | 29.43 ± 5.69         | 0.95 (-1.34 to 3.26), 0.409 |
|            | After intervention | 28.72 ± 3.63        | 29.00 ± 5.76         | -0.63 (-1.18 to -0.09), 0.021† |
| WC (cm)    | Baseline           | 93.08 ± 11.49       | 93.44 ± 11.77        | 0.35 (-5.28 to 5.98), 0.901 |
|            | After intervention | 93.75 ± 11.71       | 91.08 ± 11.41        | -2.94 (-5.25 to -0.64), 0.013† |
| HC (cm)    | Baseline           | 108.79 ± 7.74       | 110.19 ± 10.69       | 1.39 (-3.13 to 5.92), 0.540 |
|            | After intervention | 109.32 ± 8.27       | 108.86 ± 11.01       | -1.81 (-3.38 to -0.24), 0.024† |
| WHR        | Baseline           | 0.52 (-0.24 to 1.30), 0.176 | -1.32 (-2.68 to 0.03), 0.056 |
|            | After intervention | 0.85 ± 0.65         | 0.84 ± 0.05          | -0.007 (-0.03 to 0.02), 0.643 |
| WHtR       | Baseline           | 0.00 (-0.01 to 0.01), 0.678 | -0.01 (-0.02 to 0.00), 0.090 |
|            | After intervention | 0.57 ± 0.07         | 0.57 ± 0.07          | 0.00 (-0.03 to 0.03), 0.974 |

Data are presented as mean ± SD. PCOS; Polycystic ovary syndrome, CI; Confidence interval, MD; Means difference, BMI; Body mass index, WC; Waist circumference, HC; Hip circumference, WHR; Waist to hip ratio, WHtR; Waist-to- height ratio, **; P value is reported based on the analysis of, paired sample t test, and †; P value is reported based on the analysis of covariance, adjusted for energy intake and baseline values.
lipopolysaccharides (LPS) along the mucous wall and metabolic endo-toxaemia, which can ultimately lead to improvements in insulin receptor function, lower insulin levels, and increased normal ovarian function (15).

Our results confirmed improving effects of synbiotic administration on glycemic indices by lowering HOMA-IR and subsequent lowered blood glucose and insulin in the studied women. However, in a study by Karimi et al. (20) use of synbiotic supplement did not affect these parameters in women with PCOS. Non-effectiveness of synbiotics on glycemic indices has been also reported in a study on subjects with nonalcoholic steatohepatitis (30). Differences in clinical and metabolic characteristics of participants, as well as varying strains and doses of probiotics and type of prebiotics, treatment period and host gut microbiota, might contribute to controversial findings.

HDL cholesterol is considered the helpful cholesterol due to its function of transporting cholesterol in the shape of cholesterol esters to the liver for rather a hydrolysis (31). According to our results, the mean serum HDL cholesterol levels of studied subjects were lower than 50 mg/dl (normal cut-off based on National Cholesterol Education Program Adult Treatment Panel III) (32) in both groups at baseline and its level elevated in the synbiotic group at the end of the study in comparison with the placebo group. Samimi et al. (19) in their research concluded that the intervention with symbiotic for 12 weeks in PCOS patients, had significant alleviations of serum TG and VLDL cholesterol levels. No other study is available about possible effects of synbiotics on lipid profiles in PCOS.

It was proposed that probiotics may interfere in the removal of cholesterol by reducing cholesterol absorption from the intestine (33). Liong and Shah (34) showed that cholesterol conjugation to the cell wall of probiotics and their special abilities in enzymatic biliary acid decontamination lead to a decrement of serum cholesterol. Moreover, it was demonstrated that the cholesterol-lowering effects of probiotics increase with the use of prebiotics, concurrently (33).

In the present study, along with improvement in serum HDL cholesterol in the synbiotic group, no significant change was detected in other serum lipids. So, further studies are needed to investigate longer synbiotics administration effects and their precise effects on lipid metabolism.

Obesity displays a considerable role in the progress of metabolic disease in women with PCOS. Studies have indicated that the gut microbiota as an environmental factor was altered in obesity and leads to its spread (35, 36).

Our results indicated that synbiotic supplementation reduced weight and BMI and central obesity indices including WC, HC, and WHtR in the intervened group compared to the placebo group. As previously mentioned, no other study investigated possible effects of synbiotics in the form of our supplement on anthropometric characteristics in women with PCOS.

Studies showed that intestinal microbiota modifies the biological system, which results in the regulation of nutrient availability, energy storage, spread of fat mass and inflammation in the host, both of which are associated with obesity (17). The intestinal microbiota is also effective in regulating nutrient intake via the SCFA signaling function (36).

Women participated in our research were asked to follow their previous diet and physical activity, and our analysis showed that there were no significant changes in these variables during the intervention. As a result, it seems that improved obesity values in the group intervened with synbiotics, were not induced by changes in food intake or physical activity. It was possible that the reduction in obesity values in the synbiotic group might be related to improvement in HOMA-IR, at least in part. Evidence suggests that higher insulin sensitivity reduces hyperglycemia, hepatic lipid synthesis and fat accumulation in adipose tissues (37). Additionally, changes in anthropometric measurements were not mediated through apelin levels. Since, synbiotic supplementation did not affect serum apelin levels in our study.

It was suggested that synbiotics by changing the balance of intestinal microbiota (DOGMA), may affect endocannabinoid and apelinergic system. Intestinal microbiota imbalance enhances the permeability of the intestinal epithelium and consequently, the influx of LPS into the circulation, which finally leads to metabolic endotoxemia, activation of the immune system and induction of inflammation. These conditions promote the activity of the apelinergic system in the adipose tissue and the level of apelin in the serum. Thus, changes in intestinal microbiota with symbiotic play an important role in reducing apelin levels in PCOS patients (38). Karimi et al. (20) reported a significant decrease in serum apelin levels in women with PCOS following synbiotic supplementation from $27 \pm 21$ nmol/l at baseline to $14.4 \pm 4.5$ nmol/l at the end of study. Changes in the placebo group were not significant ($26 \pm 15$ nmol/l and $18.4 \pm 2.9$ nmol/l, at the beginning and the end of study, respectively). In present study, as described in results section, wide SD distribution of apelin might have contributed to non-considerable changes in concentration of this adipokine. It was also probable that dose or duration of supplementation was not adequate to affect the apelin levels in our trial. As mentioned previously, Karimi et al. (20) applied a two-time higher supplement dosage (1000 mg) for a longer period (12 weeks) and obtained significant changes in apelin levels. No other study is available about possible effects of synbiotics on apelin levels in PCOS or other diseases.

It should be noted that the exact normal range for serum apelin has not been documented yet. To date, a few studies have measured apelin in subjects with PCOS, and their results are incompatible. In the study by Olszanecka-Glinianowic et al. (24) no significant difference was seen...
in serum levels of this adipokine in PCOS and non-PCOS women. Plasma apelin-36 levels was significantly higher in normal-weight women than the obese PCOS women (3.1 ± 2.2 vs. 1.2 ± 0.7 μg/l, respectively). In another study, serum apelin levels were correlated positively with BMI, IR, serum insulin and TG in women with PCOS. Apelin levels were lower in women with PCOS than controls (194.1 ± 50.7 pg/ml vs. 292.1 ± 85.6 pg/ml, respectively) (39). Inconsistent results among the findings of the available studies may be related to the design and the demographic and genetic specifications of populations as well as the nature of apelin.

In our study, no association was found between serum apelin concentrations and values of obesity or biochemical parameters before or after interventions in either group (data are not shown). As a result, it seems that favorable changes detected in glycemic indices and lipid profile in our study were not mediated via apelin. Subsequent studies are needed to evaluate the intestinal microbiota impacts on circulating apelin as well as the role of this adipokine in the pathogenesis of PCOS.

The strength of our study was the double-blind placebo-controlled design with no drop-outs. However, the present study had some limitations such as its short study duration of 8 weeks. Also, bacterial flora changes and SCFAs were not assessed through analysis of the stool. This research included overweight or obese patients. Therefore, our findings cannot be generalized to low-weight and/or normal-weight PCOS women, various intervention periods and other kinds of synbiotics. Additional studies are warranted to identify the impacts of synbiotics on other serum adipokines and androgen status in women with PCOS.

Conclusion

It can be said that synbiotic supplementation improved glycemic indices, serum HDL cholesterol levels and obesity values in subjects with PCOS and may be useful in the control of metabolic factors and reducing adiposity in these patients. Synbiotic administration in this study did not affect serum apelin levels. It is offered that the physiopathological function of apelin and metabolic effects of synbiotics in PCOS patients be evaluated more in future studies.

Acknowledgements

We thank the Research Vice-Chancellor and Nutrition Research Center of Tabriz University of Medical Sciences, Tabriz, Iran for the financial support, and the women who took part in this study. This manuscript was written based on an M.Sc. thesis on nutrition (No.T/A/169), which was registered at Tabriz University of Medical Sciences. The authors declare no conflict of interest.

Authors’ Contributions

M.R.; Contributed to the study design and conceived the clinical trial progressing as a principal supervisor, prepared the manuscript, and reviewed the whole project drastically. S.D.; Contributed to the data collection and interpretation as a principal investigator, prepared the manuscript, and reported the final results. M.A.-J.; Performed the statistical analysis and data interpretation. L.F.; Participated in study design and patients recruitment. All authors read and approved the final version of the manuscript.

References

1. Karakas SE. New biomarkers for diagnosis and management of polycystic ovary syndrome. Clin Chim Acta. 2017; 471: 248-253.
2. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14(1): 38.
3. Zhang J, Sun Z, Jiang S, Bai X, Ma C, Peng Q, et al. Probiotic bifidobacterium lactis v9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis. Systems. 2019; 4(2): e00017-19.
4. Baillargeon JP, Nestler JE, Oslund RE, Apridonidze T, Diamanti-Kandarakis E, Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositol metabolism. Hum Reprod. 2008; 23(6): 1439-1446.
5. Youssif SD, Rashid F, Mattoo T, Shehkar C, Mudassar S, Zargar MA, et al. Does the oral contraceptive pill increase plasma intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and tumor necrosis factor-a levels in women with polycystic ovary syndrome: a pilot study. J Pediatr Adolesc Gynecol. 2017; 30(1): 58-62.
6. Butterworth J, Degruara J, Borg CM. Bariatric surgery, polycystic ovary syndrome, and infertility. J Obes. 2016; 2016: 1871594.
7. Nambari V, Vijesh VV, Lakshmanan P, Sukumar S, Suganthi R. Association of adiponectin and resistin gene polymorphisms in South Indian women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016; 200: 214-219.
8. Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an update in the management of polycystic ovary syndrome. J Obstet Gynecol Reprod Biol. 2016; 207: 214-219.
9. Ma WY, Yu TY, Wei JN, Hung CS, Lin MS, Liao YJ, et al. Plasma apelin: a novel biomarker for predicting diabetes. Clin Chim Acta. 2014; 435: 18-23.
10. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015; 36(7): 461-470.
11. Dray C, Debard C, Jager J, Disse E, Daviaud D, Martin P, et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab. 2010; 298(6): E1161-E1169.
12. Yue P, Jin H, Alliard M, Deng AC, Azuma J, Asagami T, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010; 298(1): E59-E67.
13. Benk Siffler D, Gocce C, Kessin Kurt R, Yiilmaz Alligan N, Ozturk OH, Turhan E, et al. Does polycystic ovary syndrome itself have additional effect on apelin levels? Obstet Gynecol Int. 2014; 2014: 536896.
14. Roche J, Ramí C, Reverchon M, Mellouk N, Cornuau M, Guerif F, et al. Apelin (APLN) and apelin receptor (APLNR) in human ovary: expression, signaling, and regulation of steroidogenesis in primary human luteinized granulosa cells. Biol Reprod. 2016; 95(5): 104.
15. Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)–a novel theory for the development of polycystic ovarian syndrome. Med Hypotheses. 2012; 79(1): 104-112.
16. Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. Int J Mol Sci. 2016; 17(6): 929.
17. Yoo JY, Kim SS. Probiotics and prebiotics: present status and future perspectives on metabolic disorders. Nutrients. 2016; 8(3): 173.
18. Kazemi A, Soltani S, Ghorabi S, Keshkara A, Daneshзадه E, Nasr F, et al. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic
review and meta-analysis of clinical trials. Clin Nutr. 2020; 39(3): 789-819.

19. Samimi M, Dadkhah A, Haddad Kashani H, Tajabadi-Ebrahimi M, Seyed Hosseini E, Asemi Z. The effects of synbiotic supplementation on metabolic status in women with polycystic ovary syndrome: a randomized double-blind clinical trial. Probiotics antimicrobes Proteins, 2019; 11(4): 1355-1361.

20. Karimi E, Monir A, Yaseri M, Shirzad N, Sepidarkish M, Hossein-Boroujerdi M, et al. Effects of synbiotic supplementation on metabolic parameters and apelin in women with polycystic ovary syndrome: a randomised double-blind placebo-controlled trial. Br J Nutr. 2018; 119(4): 398-406.

21. Nasri K, Jamilian M, Rahmani E, Bahmani F, Tajabadi-Ebrahimi M, Asemi Z. The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord. 2018; 18(1): 21.

22. Lindheim L, Bashir M, Münzker J, Trummer C, Zachhuber V, Leber B, et al. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study. PLoS One. 2017; 12(1): e0168390.

23. Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M, et al. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017; 20(4): 254-261.

24. Olszanecka-Glinianowicz M, Madej P, Nylec M, Owczarek A, Szanecki W, Skałba P, et al. Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances. Clin Endocrinol (Oxf). 2013; 79(2): 238-242.

25. Bala M, Meenakshi, K M, Gupta A. Correlation of HbA1C levels with body mass index in newly diagnosed polycystic ovary syndrome. EJIFCC. 2017; 28(3): 196-204.

26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412-419.

27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6): 499-502.

28. Boulangé CL, Neves AL, Chiloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016; 8(1): 42.

29. Esmaeilionezhad Z, Babajafari S, Sohrabi Z, Eskandari MH, Amooee S, Barati-Boldajir R. Effect of synbiotic pomegranate juice on glycemic, sex hormone profile and anthropometric indices in PCOS: A randomized, triple blind, controlled trial. Nutr Metab Cardiovasc Dis. 2019; 29(2): 201-208.

30. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012; 57(2): 545-553.

31. Razmpooosh E, Javadi A, Eftekhad HS, Mirmiran P, Javadi M, Yousefnejad A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo controlled trial. Diabetes Metab Syndr. 2019; 13(1): 175-182.

32. Hosseini-Esfahani F, Bahadoran Z, Moslehi N, Aghari G, Yuzbashian E, Hosseinpour-Niazi S, et al. Metabolic syndrome: findings from 20 years of the Tehran lipid and glucose study. Int J Endocrinol Metab. 2018; 16(4 Suppl): e84771.

33. Roselino MN, Pauly-Silveira ND, Cavallini DC, Celiberto LS, Pinto RA, Vendramini RC, et al. A potential probiotic product improves the lipid profile of diabetic rats. Lipids Health Dis. 2012; 11: 114.

34. El Hayek S, Bilar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016; 7: 124.

35. Bala M, Meenakshi, K M, Gupta A. Correlation of HbA1C levels with body mass index in newly diagnosed polycystic ovary syndrome. EJIFCC. 2017; 28(3): 196-204.

36. Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes. 2014; 5(1): 3-17.

37. Altinkaya SO, Nergiz S, Küçük M, Yüksel H. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014; 176: 168-172.